By LINDA A. JOHNSON AP Business Writer TRENTON, N.J. (AP) — The U.S. Patent & Trademark Office on Tuesday issued a notice allowing drugmaker Pfizer Inc. to correct a technical defect in one of the patents involving Pfizer’s cholesterol medicine Lipitor, the world’s top-selling drug. The decision will result in reissuance of the drug’s key patent and maintain that patent’s June 2011 expiration date, crucial to Pfizer because Lipitor brings the company nearly $13 billion in annual sales. That revenue has made the drug, and New York-based Pfizer, the target of litigation by generic drugmakers hoping to roll out cheaper versions earlier and capture part of the market for one of the top classes of drugs. “We have said all along that we had strong arguments for securing the reissue of the patent, and after a vigorous and thorough examination, the Patent Office agreed with this conclusion,” Raymond F. Kerins, vice president of worldwide communications at Pfizer, said in a statement. Tuesday’s patent office decision resulted from litigation that began after India’s largest drugmaker, Ranbaxy Laboratories Ltd., in 2002 sought U.S. Food and Drug Administration approval to sell a generic version of Lipitor, which is known chemically as atorvastatin. Ranbaxy challenged both Lipitor’s basic patent and a second one. That patent, “the ‘995 enantiomer patent,” is one “most specifically focused on the molecule that is the active ingredient in Lipitor,” according to Pfizer spokesman Chris Loder. An enantiomer is a structural mirror image, or one of the two forms of a protein or other molecule often found in nature — a left-handed version and a right-handed version. Many drugs include both versions, but Lipitor’s active ingredient is just one of those “handed” versions, with the molecule attached to a calcium salt that makes it both very stable and active. The ‘995 patent covers that specific structure, Loder said. Pfizer had sued Ranbaxy to block its challenge of both patents and initially won in federal court in Delaware, but a Court of Appeals ruling in December 2006 found the ‘995 patent had a technical defect: one claim within it contained an improper cross reference to another claim in the patent. The following month, to resolve the issue, Pfizer applied with the patent office to correct the defect by removing the cross reference and have the patent reissued. Two years later, the patent office ruled it will reissue the patent, as revised, if Pfizer pays a fee of $1,510 within three months. The June 2011 expiration date includes a six-month extension of the original expiration date granted because Pfizer did research after the drug was approved to determine its safety and effectiveness in children — a standard move by drug companies to preserve revenue of their most lucrative drugs. However, Pfizer’s litigation with Ranbaxy also involved three other patents that ran through 2016 and 2017. Last June, the companies settled that lawsuit with an agreement essentially giving Ranbaxy license to those patents and allowing it to begin selling generic Lipitor as of Nov. 30, 2011. As the first company to seek FDA approval to sell a generic, it can do so for six months exclusively. Two other generic drugmakers now in litigation with Pfizer could sell their own versions at the end of May 2012 at the earliest, but if they did so would still risk liability for violating some of the other Lipitor patents, including the ones ending in 2016 and 2017.
